OCS
NASDAQ
$11.73
Oculis Holding AG (OCS)
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
This company is also listed under the following ticker: OCSAW.
Website: https://oculis.comSector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $37.54 (+220.03%)
Market Cap
$773M
Free Cash Flow Yield
-10.28%
Beta (5Y)
0.66
Price Chart
Valuation
Market Cap$773M
P/S705.51
P/B3.22
Profitability
Total Revenue (TTM)$631K
Gross Profit (TTM)-$69M
EBITDA-$118M
Operating Margin-10396%
EPS-$2.17
Financial Health
Debt-to-Equity1.1%
Free Cash Flow Yield-10.28%
Growth & Risk
Beta (5Y)0.66
Sharpe Ratio-0.36